Following a curious tweet on her ‘sun allergy’ we invited Amanda from Texas to share her experiences as a guest blogger in the hope that they may help others. This is the second of two parts, you can read part one here.
Hiding from the sun wasn’t an option. Granted, I was reluctant to incur the wrath of UV light: the itching, the bumps, the disfiguration that affected my confidence. Thankfully my PLE was confined to my arms.
Yet, with dermatologists telling me nothing could be done outside an occasional cortisone injection, I was determined to explore any and all treatment options. (more…)
A week ago we saw the close of the 
As many of you may know, this week saw Clinuvel hold its Annual General Meeting in the Melbourne Town Hall. As managing director I welcome these opportunities where I am able to meet and talk to the people whom Clinuvel considers integral to the company and its existence; the Board of Directors sees Clinuvel’s investors as unique. In Clinuvel, an investor has to fundamentally believe in the premise of offering pharmaceutical photoprotection, a novel option, an innovative approach to skin disorders.
Allergan’s lawsuit filed against the FDA presents a relatively novel case in addressing the requirements of drug developers in relation to off-label use of drugs by physicians.
Today, and in the coming weeks I shall review the increasingly complex phenomenon in the pharmaceutical industry called off-label drug use. 
This is a continuation of the post 
EPP is a rare condition, and the most acute indication for which we are exploring a clinical treatment with afamelanotide. Simply put, EPP is an absolute light intolerance brought about by a build up of photosensitive compounds in the skin of the sufferer.
In Clinuvel’s search to demonstrate the effect of its drug to reduce symptoms caused by light in the visible and invisible spectrum, the team has started to carry out human trials in Photodynamic Therapy (PDT). This indication stands out among Clinuvel’s current series of clinical trials as it is aimed at reducing symptoms caused by another cancer treatment (adjunct treatment details can be found 
